Thrombogenics Says Trial For Microplasmin In Eye Disease Shows Positive Results

Wednesday, December 5, 2007

Forbes

Biotech company ThromboGenics NV said its Phase II trial for microplasmin showed positive clinical results in patients with vitreomacular traction.

Keep up with our latest articles, news and events. Plus, get special offers and more delivered to your inbox.

Like us
on Facebook Follow us
on Twitter

OphthalmologyWeb wants to hear from you. Submit your case studies, clinical pearls, practice management tips, editorial, or other manuscripts.

AdGlare Leaderboard